(Q40026025)

16 September 2017

Reassessing the risk of natalizumab-associated PML. (English)

1 reference

PubMed ID

26843383

Erratum to: Reassessing the risk of natalizumab-associated PML.

16 September 2017

corrigendum / erratum

0 references

author name string

Joseph R Berger

series ordinal

1

1 reference

PubMed ID

26843383

16 September 2017

Robert J Fox

series ordinal

2

1 reference

16 September 2017

3 February 2016

1 reference

16 September 2017

Journal of NeuroVirology

1 reference

16 September 2017

22

1 reference

16 September 2017

4

1 reference

16 September 2017

533-535

1 reference

https://scigraph.springernature.com/pub.10.1007/s13365-016-0427-6

16 September 2017

0 references

cites work

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1007%2FS13365-016-0427-6

Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-016-0427-6

Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-016-0427-6

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-016-0427-6

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-016-0427-6

Risk stratification and patient counseling for natalizumab in multiple sclerosis

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26843383

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S13365-016-0427-6

1 reference

16 September 2017

1 reference

PubMed ID

26843383